

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Lumu, William; Kampiire, Leaticia; Akabwai, George Patrick; Ssekitoleko, Richard; Kiggundu, Daniel Ssekikubo; Kibirige, Davis; (2017) Dyslipidaemia in a Black African diabetic population: burden, pattern and predictors. BMC research notes, 10 (1). 587-. ISSN 1756-0500 DOI: <https://doi.org/10.1186/s13104-017-2916-y>

Downloaded from: <http://researchonline.lshtm.ac.uk/id/eprint/4655709/>

DOI: <https://doi.org/10.1186/s13104-017-2916-y>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by/2.5/>

<https://researchonline.lshtm.ac.uk>

RESEARCH NOTE

Open Access



# Dyslipidaemia in a Black African diabetic population: burden, pattern and predictors

William Lumu<sup>1</sup>, Leaticia Kampiire<sup>2</sup>, George Patrick Akabwai<sup>3</sup>, Richard Ssekitoleko<sup>4</sup>, Daniel Ssekikubo Kiggundu<sup>5</sup> and Davis Kibirige<sup>6\*</sup>

## Abstract

**Objectives:** This study sought to assess the burden, pattern and predictors of dyslipidaemia in 425 adult diabetic patients in Uganda.

**Results:** The median (IQR) age of the study participants was 53 (43.5–62) years with a female majority (283, 66.9%). Dyslipidaemia defined as presence of  $\geq 1$  lipid abnormalities was observed in 374 (88%) study participants. Collectively, the predictors of dyslipidaemia were: female gender, study site (private hospitals), type of diabetes (type 2 diabetes mellitus), statin therapy, increased body mass index and diastolic blood pressure. Proactive screening of dyslipidaemia and its optimal management using lipid lowering therapy should be emphasised among adult diabetic patients in Uganda.

**Keywords:** Dyslipidaemia, Burden, Predictors, Adult diabetics, Uganda

## Introduction

Globally, cardiovascular diseases (CVD) account for the greatest adult morbidity and mortality. According to the 2012 World Health Organisation estimates, about 17.5 million people died from CVD. This was equivalent to 31% of all global deaths and the majority (about 80%) of these deaths occurred in low and middle income countries [1]. Diabetes mellitus (DM) is a recognised coronary artery disease equivalent which accounts for about 75% of atherosclerotic related mortality in diabetic patients [2]. Diabetic dyslipidaemia is defined by a high plasma TGL concentration, low HDL cholesterol concentration and increased concentration of small dense LDL-cholesterol particles [3].

Despite compelling evidence that dyslipidaemia is highly prevalent among patients with type 2 diabetes mellitus (T2DM), there are few published studies about diabetes-dyslipidaemia co-morbidity in Uganda [4–6]. These available studies have limitations like: small sample sizes, being single hospital based, the varying study

definitions of dyslipidaemia and did not investigate the independent predictors of dyslipidaemia.

This study investigated the burden, pattern and predictors of dyslipidaemia in Uganda.

## Main text

### Methods

This analytical cross sectional study was performed from 1st September 2014 to 31st July 2015 at outpatient diabetic clinics of 3 urban tertiary hospitals in Kampala, Uganda. These hospitals serve an urban population of approximately 2 million people. The outpatient diabetes clinics in these hospitals function only once a week and an average of 35 patients are reviewed by either a general practitioner or specialist physician. Comprehensive diabetic education, body mass index (BMI), blood pressure (BP) and fasting blood sugar measurement are regularly done at every clinical review.

The patients that were eligible for enrolment in the study were those aged  $\geq 18$  years with a confirmed diagnosis of diabetes using either fasting blood glucose levels, an oral glucose tolerance test, HbA1c or random blood sugar level in the presence of symptoms of diabetes, had been receiving treatment at the study centre for a minimum of 6 months and had provided informed consent.

\*Correspondence: kibirigedavis@gmail.com

<sup>6</sup> Department of Medicine, Uganda Martyrs Hospital Lubaga, P.O. BOX 7146, Kampala, Uganda

Full list of author information is available at the end of the article

These were enrolled consecutively until the desired sample size was reached.

All critically ill patients that required intensive care in-patient management were excluded from the study.

#### Sample size calculation

Basing on one of the objectives of the study i.e. to determine the burden of dyslipidaemia, the prevalence (P) of low high dense lipoprotein cholesterol (HDL) of  $\leq 40$  mmol/l of 52% as reported in the study by Kamara et al. among 150 adult diabetic patients in Southern Western Uganda was used as the prevalence of dyslipidaemia [5]. Using the formula:  $n = Z^2P(1 - P)/d^2$  where Z (normal value corresponding to the 95% confidence interval) = 1.96, P = 0.52 and d = 0.05, a sample size of 383 adult diabetic patients was obtained. However, a total of 425 adult patients were enrolled.

#### Data collection

Using a pre tested questionnaire, information about the study participants' socio-demographic characteristics, co-morbidities, type of diabetes, age at diagnosis of DM, duration since diagnosis and drug history was collected by the trained study team. All study participants had their BP, height and weight (for BMI calculation) measured. These obtained study variables are known to be associated with dyslipidaemia in clinical studies and literature.

A venous blood sample was withdrawn from each patient after providing informed consent by the study phlebotomist for analysis of the glycated haemoglobin (HbA1c), low density lipoprotein cholesterol (LDL), HDL, triglyceride (TGL) and total cholesterol (TC) concentrations using a full automated COBAS® integra 400 (Roche Diagnostics GmbH) machine at each participating hospital.

#### Statistical analysis

The collected study information was entered into Microsoft Excel data base and analysed using Stata software version 12.1. The patient characteristics of interest were reported as frequency and percentage for categorical variables and median and inter-quartile range (IQR) for continuous variables which were not normally distributed.

Dyslipidaemia was defined as presence of  $\geq 1$  lipid abnormality among the study participants. The following lipid concentrations were considered abnormal as according to the 2015 American Diabetes Association standards of care of diabetes [7] and the 2014 National Lipid Association annual summary of clinical lipidology summary on patient-centred evaluation, management and care of patients with dyslipidaemia [8]: LDL  $> 2.6$  mmol/l, HDL  $< 1.3$  mmol/l, TGL  $> 1.7$  mmol/l, TC  $> 5$  mmol/l and non HDL  $< 3.4$  mmol/l. Non HDL, an integral

lipid parameter in lipidology was calculated using the formula: non HDL = TC-HDL in mmol/l [8]. Frequencies of patients with abnormal concentrations for each lipid parameter and those with  $\geq 1$  lipid abnormality were calculated to determine the burden and pattern of dyslipidaemia. To determine associations between the study variables of interest and the 3 abnormal lipid parameters of interest i.e. elevated LDL, TGL and non HDL, bivariate analyses using Chi square test was performed. All variables with a p value of  $< 0.2$  were considered significant at bivariate analysis. Multivariate analysis using logistic regression was then performed to identify the independent predictors. A p value of  $< 0.05$  and confidence intervals not including 1 were considered to be statistically significant.

## Results

### Socio-demographic and clinical characteristics

The median age of the study participants was 53 (43.5–62) years. Females constituted the greatest proportion of study participants (284, 66.9%) and hypertension comorbidity was reported in 292 (68.9%) study participants (summarised in Table 1).

### Burden, pattern, management patterns of dyslipidaemia

Dyslipidaemia was documented in 374 study participants, accounting for 88%. Elevated LDL concentrations was the commonest single lipid abnormality (60.9%) followed by elevated TC (43.1%), TGL (42.1%), non HDL (39.3%) and low HDL concentrations (29.2%). Severe hypertriglyceridemia defined as TGL levels  $\geq 5.7$  mmol/l was noted in only 4 (1%) study participants. Few patients were on lipid lowering drugs (LLD) i.e. statins with or without fibrates (20.9%) (summarised in Table 1).

### Socio-demographic, clinical and laboratory characteristics of the study participants at bivariate analysis

The variables that were statistically associated with the elevated lipid parameters of interest are shown in italics in Tables 2, 3 and Additional file 1: Table S1 and Additional file 2: Table S2. Additional file 1: Table S1 is uploaded as an additional file.

### Independent predictors of elevated LDL, TGL and non HDL concentrations at multivariate analysis

The following identified independent predictors were identified after logistic regression:

- Female gender (AOR 2.33 95% CI 1.43–3.80,  $p = 0.001$ ), study site or private hospitals (AOR 0.54 95% CI 0.32–0.89,  $p = 0.017$ ), type 2 DM (AOR 4.76 95% CI 2.03–11.14,  $p < 0.005$ ), use of statin therapy (AOR 0.46 95% CI 0.24–0.90,  $p = 0.022$ ) and diastolic

**Table 1 Socio-demographic and clinical characteristics of the study participants (N = 425)**

Variable	N (%)
Age in years, median (IQR)	53 (43.5–62)
Gender, n (%)	
Male	140 (33.02)
Female	284 (66.98)
Education level, n (%)	
None	38 (8.96)
Primary	165 (38.92)
Secondary	141 (33.25)
Tertiary	79 (18.63)
Occupation, n (%)	
Employed	212 (50)
Unemployed	212 (50)
Marital status, n (%)	
Married	259 (61.08)
Cohabiting	10 (2.36)
Single	47 (11.08)
Divorced	41 (9.67)
Widow/widowed	67 (15.80)
Place of residence	
Rural	136 (32.08)
Urban	288 (67.92)
Study site	
Government	199 (46.82)
Private	226 (53.18)
Smoking	
Yes	10 (2.35)
No	415 (97.65)
Known HT	
Yes	292 (68.87)
No	132 (31.13)
HIV co-existent	
Yes	17 (4.00)
No	408 (96.00)
FH-DM	
Yes	264 (62.26)
No	160 (37.74)
Type of DM	
Type 1 DM	55 (13.13)
Type 2 DM	364 (86.87)
Drug history	
Diet alone	3 (0.71)
Metformin alone	79 (18.59)
Met + SU	127 (29.88)
Met + SU + TZD	16 (3.76)
Met + incretins	8 (1.88)
Insulin alone/+ met	188 (44.34)
Statins	89 (20.94)

**Table 1 continued**

Variable	Median (IQR), N = 425
Age at diagnosis in years	47 (37–55)
Duration with DM in years	4.5 (2–10)
BMI in kg/m <sup>2</sup>	27 (23–30.6)
HbA1c (%)	9 (6.8–12.4)
LDLC in mmol/l	2.9 (2.3–3.84)
HDLC in mmol/l	1.19 (0.9–1.42)
TC in mmol/l	4.82 (4.1–5.71)
TGL in mmol/l	1.6 (1.23–2.2)
LDLC > 2.6 mmol/l	259 (60.9)
TC > 5 mmol/l	183 (43.1)
HDLC < 1 mmol/l	124 (29.2)
TGL > 1.7 mmol/l	179 (41.2)
TGL ≥ 5.7 mmol/l	5 (1.2)
Non HDLC < 3.4 mmol/l	167 (39.3)
TC/HDLC ratio < 4.5 mmol/l	235 (55.3)
All normal LDLC, TGL, TC and HDLC concentrations	5 (12)
SBP, mmHg	139 (124–155)
DBP, mmHg	80 (73–91)

DM diabetes mellitus, HT hypertension, FH family history, SU sulphonylureas, Met metformin, TZD thiazolididiones, BMI body mass index, HbA1c glycated haemoglobin, LDLC low density lipoprotein cholesterol, HDLC high density lipoprotein cholesterol, TC total cholesterol, TGL triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, IQR inter quartile range

BP (AOR 1.03 95% CI 1.01–1.05,  $p = 0.014$ ) for elevated LDLC concentrations.

- Study site or private hospitals (AOR 0.59 95% CI 0.37–0.96,  $p = 0.032$ ) and increased BMI (AOR 1.06 95% CI 1.02–1.10,  $p = 0.002$ ) for elevated TGL concentrations.
- Female gender (AOR 2.20 95% CI 1.37–3.53,  $p = 0.001$ ), study site or private hospitals (AOR 0.48 95% CI 0.29–0.79,  $p = 0.004$ ), type 2 DM (AOR 3.13 95% CI 1.53–6.40,  $p = 0.002$ ) and use of statin therapy (AOR 0.43 95% CI 0.23–0.80,  $p = 0.008$ ) for elevated non HDLC concentrations (summarised as Additional file 1: Table S2 which is uploaded as an additional file).

## Discussion

This cross sectional study shows that dyslipidaemia was prevalent in the majority of the surveyed adult diabetic population. The rate of use of LLD was also low. The documented pattern of dyslipidaemia is consistent with what is described as diabetic dyslipidaemia [3].

Dyslipidaemia has been documented to be highly prevalent in African diabetic patients in most studies [6, 9–14]. Despite this high prevalence, varied patterns of

**Table 2 Suboptimal LDLC concentrations in relation to socio-demographic and clinical characteristics at bivariable analysis**

Characteristic	LDLC > 2.6 mmol/l	LDLC ≤ 2.6 mmol/l	OR 95% CI	p value
Age, median (IQR)	55.5 (48–67)	53 (43–62)	1.01 (0.99–1.02)	0.224
Gender				
Male	71 (51.45)	67 (49.55)	1	0.001
Female	188 (68.12)	88 (31.88)	2.02 (1.33–3.07)	
Type of hospital				
Government	133 (66.83)	66 (33.17)	1	0.084
Private	126 (58.60)	89 (41.40)	0.76 (0.47–1.05)	
Place of residence				
Rural	85 (62.96)	50 (37.04)	1	0.906
Urban	174 (62.37)	105 (37.63)	0.97 (0.64–1.49)	
Smoking				
Smoker	8 (88.89)	1 (11.11)	1	0.135
Non smoker	251 (61.98)	154 (38.02)	0.20 (0.03–1.64)	
Occupation				
Employed	132 (64.08)	74 (35.92)	1	0.526
Unemployed	127 (61.06)	81 (38.94)	0.88 (0.59–1.31)	
Co-existing HT				
Yes	191 (67.25)	93 (32.75)	1	0.004
No	68 (52.31)	62 (47.69)	0.53 (0.35–0.82)	
DM type				
Type 1 DM	21 (38.18)	34 (61.82)	1	<0.005
Type 2 DM	234 (66.10)	120 (33.90)	3.16 (1.76–5.68)	
Family history of DM				
Yes	170 (66.15)	87 (33.85)	1	0.054
No	89 (56.69)	68 (43.31)	0.67 (0.45–1.01)	
HIV co-morbidity				
Yes	10 (58.82)	7 (41.18)	1	0.745
No	249 (62.72)	148 (37.28)	1.18 (0.44–3.16)	
Median (IQR) age at diagnosis	53.5 (49–58)	46 (37–55)	1.01 (0.99–1.02)	0.379
Median (IQR) years duration with DM.	3.5 (1–14)	4.5 (2–10)	1.02 (0.99–1.06)	0.165
BMI in kg/m <sup>2</sup> median (IQR)	28.7 (25–34.3)	27 (23–30.6)	1.04 (1.00–1.07)	0.041
BP in mmHg, median (IQR)				
SBP	130 (20–150)	139 (24–156)	1.01 (1.00–1.02)	0.015
DBP	70 (70–78)	80 (74–91)	1.02 (1.01–1.04)	0.002
HbA1c (%), median (IQR)	8.95 (6.8–10.1)	9 (6.9–12.4)	0.98 (0.93–1.03)	0.488
Drugs				
Insulin therapy	106 (58.89)	74 (41.11)	1	0.113
On OHA	151 (66.52)	76 (33.48)	1.39 (0.92–2.08)	
Statin therapy n (%)				
No	199 (60.86)	128 (39.14)	1	0.166
Yes	60 (68.97)	27 (31.03)	0.70 (0.42–1.16)	

DM diabetes mellitus, HT hypertension, FH family history, OHA oral hypoglycaemic agents, BMI body mass index, HbA1c glycated haemoglobin, SBP systolic blood pressure, DBP diastolic blood pressure

dyslipidaemia have been described among African diabetic patients. A study done in a university referral hospital in Southern Ethiopia among 295 diabetics reported low HDLC concentration to be the most prevalent lipid

abnormality (87.8%), followed by increased LDLC concentrations (63.7%), increased TC (34.6%) and increased TGL (29.8%) [9]. A similar pattern of dyslipidaemia was also noted in a small South African urban study of 150

**Table 3 Suboptimal non HDLC concentrations in relation to socio-demographic and clinical characteristics at bivariable analysis**

Characteristic	Non HDLC $\geq$ 3.4 mmol/l	Non HDLC < 3.4 mmol/l	OR 95% CI	p value
Age, median (IQR)	56 (48–67)	53 (43–61)	1.02 (1.01–1.04)	0.001
Gender				
Male	65 (47.10)	73 (52.90)	1	<0.005
Female	181 (65.82)	94 (34.18)	2.16 (1.43–3.28)	
Type of hospital				
Government	126 (63.32)	73 (36.68)	1	0.134
Private	120 (56.07)	94 (43.93)	0.74 (0.50–1.10)	
Place of residence				
Rural	85 (63.43)	49 (36.57)	1	0.267
Urban	161 (57.71)	118 (42.29)	0.79 (0.51–1.20)	
Smoking				
Smoker	6 (66.67)	3 (33.33)	1	0.662
Non smoker	240 (59.41)	167 (40.44)	0.73 (0.18–2.97)	
Occupation				
Employed	122 (59.22)	84 (40.78)	1	0.888
Unemployed	124 (59.90)	83 (40.10)	1.03 (0.69–1.52)	
Co-existing HT				
Yes	179 (63.25)	104 (36.75)	1	0.025
No	67 (51.54)	63 (48.46)	0.62 (0.41–0.94)	
DM type				
Type 1 DM	16 (29.09)	39 (70.91)	1	<0.005
Type 2 DM	227 (64.31)	126 (35.69)	4.39 (2.36–8.17)	
Family history of DM				
Yes	162 (63.04)	95 (36.96)	1	0.066
No	84 (53.85)	72 (46.15)	0.68 (0.46–1.02)	
HIV co-morbidity				
Yes	9 (52.94)	8 (47.06)	1	0.571
No	237 (59.85)	159 (40.15)	1.32 (0.50–3.51)	
Median age at diagnosis	53 (48–58)	46 (37–55)	1.03 (1.01–1.04)	0.001
Median (IQR) years duration with DM.	6 (1–15)	4 (2–10)	1.02 (0.99–1.05)	0.265
BMI in kg/m <sup>2</sup> median (IQR)	28.7 (25–34.3)	27 (23–30.6)	1.07 (1.03–1.11)	<0.005
BP in mmHg, median (IQR)				
SBP	130 (120–150)	139 (124–156)	1.01 (1.00–1.02)	0.020
DBP	70 (70–78)	80 (74–91)	1.02 (1.01–1.03)	0.008
HbA1c (%)	9.2 (6.8–10.1)	9 (6.85–12.4)	1.00 (0.95–1.05)	0.967
Drugs				
Insulin therapy	94 (52.22)	86 (47.78)	1	0.005
On OHA	149 (65.93)	77 (34.07)	1.77 (1.18–2.65)	
On statin therapy n (%)				
Yes	184 (56.44)	142 (43.56)	1	0.013
No	62 (71.26)	25 (28.74)	0.52 (0.31–0.87)	

DM diabetes mellitus, HT hypertension, FH family history, OHA oral hypoglycaemic agents, BMI body mass index, HbA1c glycated haemoglobin, SBP systolic blood pressure, DBP diastolic blood pressure

adult diabetic patients (low HDLC-60.7%, increased LDLC-49.3%, increased TGL-45.3% and increased TC-29.3%) [11]. Results from the diabetes care study in Nigeria (Diabcare Nigeria study) in 531 diabetic patients

reported low HDLC (76.3%) and increased TGL (60.7%) as the predominant lipid abnormalities [12]. The largest study assessing quality of diabetes care in 6 sub-Saharan African countries (Diabcare Africa study) reported



suboptimal TC and HDL concentrations in 36.2 and 39.4% of the study participants respectively. No study participant had elevated TGL concentrations despite the high prevalence of suboptimal glycaemic control (71% having HbA1c  $\geq$  6.5%) [13].

In our study, increased LDLC concentrations was the most prevalent, followed by elevated TC, TGL and low HDLC concentrations. Severe TGL defined as concentrations  $\geq$  5.7 mmol/l were uncommon in our study population.

Several reasons could explain the high prevalence of dyslipidaemia reported in our study and other similar African studies. Low rates of screening for dyslipidaemia and use of LLD have been noted in the majority of the sub Saharan African countries, possibly due to knowledge gaps among clinicians, low access to LLD and prohibitive costs of LLD and lipid profile testing. Two retrospective chart based studies done in outpatient diabetic clinics in Uganda [6] and South Africa [14] reported only 14 and 26% of the study participants having ever done a lipid profile assessment at least once in the previous 12 months and only 20.4 and 26.2% of the study participants respectively were receiving LLD. The Diabcare Africa study reported that about 45% of the study participants had ever performed a lipid profile assessment at least once in the past 1 year and only 13% were on LLD [13]. The LLD were reported to be unaffordable by similar studies performed in Cameroon [15] and in Benin, Sudan and Eriteria [16] reported LLD.

#### Predictors of abnormal LDLC, TGL and non HDLC concentrations

Female gender, having type 2 DM, increased BMI and diastolic BP increased the likelihood of having abnormal LDLC, TGL and non HDLC concentrations while the use of LLD and receiving diabetes care from a private hospital reduced the likelihood.

An increased rate of dyslipidaemia among female diabetic patients has also been reported by studies performed in Ethiopia [9] and Botswana [10]. Compelling evidence suggests that dyslipidaemia is a common metabolic abnormality in type 2 DM compared to type 1 DM and in obese or overweight patients. Increased diastolic BP or hypertension and type 2 DM is part of the intimate cluster of metabolic disorders in metabolic or insulin resistance syndrome [3].

Unequivocal evidence supports the use of lifestyle modification and LLD in the management of dyslipidaemia among adult diabetic patients [3].

#### Conclusions and recommendations

Dyslipidaemia is frequent among these adult diabetic patients in Uganda. The frequency of use of LLD was

low. Due to this documented high prevalence, proactive screening for dyslipidaemia among adult diabetic patients should be encouraged. In addition to encouraging lifestyle measures, it is imperative that ready access to affordable lipid lowering drugs for optimal management of dyslipidaemia is improved in Uganda.

#### Limitations

We cannot generalise these findings to the entire adult diabetic population in Uganda because the study was only done in urban tertiary health centres.

#### Additional files

**Additional file 1.** Suboptimal TGL concentrations in relation to socio-demographic and clinical characteristics at bivariable analysis.

**Additional file 2.** Independent predictors of elevated LDLC, TGL and non HDLC concentrations at multivariable analysis.

#### Abbreviations

DM: diabetes mellitus; HT: hypertension; LDLC: low dense lipoprotein cholesterol; HDLC: high dense lipoprotein cholesterol; TGL: triglycerides; CVD: cardiovascular diseases; T2DM: type 2 diabetes mellitus; BP: blood pressure; HbA1c: glycated haemoglobin; BMI: body mass index; LLD: lipid lowering drugs; IQR: interquartile range.

#### Authors' contributions

WL, GPA, RS, DK1 and DK2 collectively contributed to the design of the study, data collection, drafting of the initial manuscript, appraisal and approval of the final submitted manuscript. DK2, RS and LK performed the statistical analysis. All authors read and approved the final manuscript.

#### Author details

<sup>1</sup> Department of Medicine and Diabetes/Endocrine Unit, Mengo Hospital, Kampala, Uganda. <sup>2</sup> Infectious Diseases Research Collaboration, Kampala, Uganda. <sup>3</sup> Baylor College of Medicine Children's Foundation, Kampala, Uganda. <sup>4</sup> Infectious Disease Unit, Mulago National Referral and Teaching Hospital, Kampala, Uganda. <sup>5</sup> Nephrology Unit, Mulago National Referral and Teaching Hospital, Kampala, Uganda. <sup>6</sup> Department of Medicine, Uganda Martyrs Hospital Lubaga, P.O. BOX 7146, Kampala, Uganda.

#### Acknowledgements

We are truly grateful to all the study participants, the entire research team and the Uganda Diabetes Association for funding this research project.

#### Competing interests

DK2 works in the medical unit of GlaxoSmithKline (GSK) pharmaceutical Kenya Limited in Uganda. GSK did not participate in the study funding, design or analysis of the data. The views expressed in this manuscript are solely the author's (DK2). The rest of the authors declare no competing interests.

#### Availability of data and materials

The data set in form of an excel file supporting the results of this article is available when requested from the corresponding author.

#### Consent for publication

Not applicable.

#### Ethics approval and consent to participate

Ethical approval was provided by the institutional review boards of Makerere University College of Health Sciences, Mengo hospital and Our Lady of Conso-lata hospital Kisubi. All study participants provided written informed consent to participate in the study.

**Funding**

This study was supported by the Uganda Diabetes Association, a local professional association for diabetic patients and healthcare practitioners in Uganda.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 23 August 2017 Accepted: 3 November 2017

Published online: 09 November 2017

**References**

1. WHO. Cardiovascular diseases. <http://www.who.int/mediacentre/factsheets/fs317/en/>. Accessed 10 Dec 2015.
2. Haffner S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998;339:229–34.
3. Mooradian A. Dyslipidemia in type 2 diabetes mellitus. *Nat Clin Pract Endocrinol Metab*. 2009;5(3):150–9.
4. Akabwayi G, Kibirige D, Mutebi E, Mugenyi L, Kaddumukasa M, Opio C, et al. Vitamin B12 deficiency among black adult diabetic patients in Uganda: relation to glycaemic control and haemoglobin concentration. *J Diabetes Metab Disord*. 2016;15:26.
5. Kamara N, Asiiimwe S. Dyslipidaemia and hypertension among adults with diabetes in rural Uganda. *Trop Dr*. 2010;40:41–2.
6. Kibirige D, Atuhe D, Sebulya R, Mwebaze R. Suboptimal glycaemic and blood pressure control and screening for diabetic complications in adult ambulatory diabetic patients in Uganda: a retrospective study from a developing country. *J Diabetes Metab Disord*. 2014;13:40.
7. Standards of Medical Care in Diabetes-2015: summary of revisions. *Diabetes Care*. 2015;38(Suppl. 1):S4.
8. Bays H, Jones P, Brown W, Jacobson T. National lipid association annual summary of clinical lipidology 2015. *J Clin Lipidol*. 2014;8:S1–36.
9. Ambachew H, Shimelis T, Lemma K. Dyslipidemia among diabetic patients in Southern Ethiopia: cross-sectional study. *J Diabetes Endocrinol*. 2015;6(4):19–24.
10. Addisu Y. Lipid profile among diabetes patients in Gaborone, Botswana. *S Afr Med J*. 2006;96(2):147–8.
11. Klisiewicz A, Raal F. Sub-optimal management of type 2 diabetes mellitus—a local audit. *JEMDSA*. 2009;14(1):13–6.
12. Chineye S, Uloko A, Ogbera A, et al. Profile of Nigerians with diabetes mellitus-diabcare Nigeria study group (2008): results of a multicentre study. *Indian J Endocrinol Metab*. 2012;16(4):558–64.
13. Sobngwi E, Ndour-Mbaye M, Boateng K, et al. Type 2 diabetes control and complications in specialised diabetes care centres of six sub-Saharan African countries: the Diabcare Africa study. *Diabetes Res Clin Pract*. 2012;95:30–6.
14. Webb E, Rheeder P, Van Zyl D. Diabetes care and complications in primary care in the Tshwane district of South Africa. *Primary Care Diabetes*. 2015;9:147–54.
15. Jingi A, Noubiap J, Onana A, et al. Access to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: cost, availability and affordability in the west region of Cameroon. *PLoS ONE*. 2014;9(11):e111812.
16. Mendis S, Fukino K, Cameron A, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. *Bull World Health Org*. 2007;85:279–88.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

